An observational cohort study to assess the clinical impact of comprehensive genomic profiling in metastatic lung cancer patients


The ASPiRATION program is a pioneering partnership between government, industry and academia. The study is led by TOGA, in collaboration with Omico (Australian Genomic Cancer Medicine Centre) and the NHMRC Clinical Trials Centre (CTC). The program is supported by funding from the federal government’s Medical Research Future Fund (MRFF) and Roche.

ASPiRATION is an observational cohort study, which will screen tumour tissue from 1000 people from anywhere in Australia with newly diagnosed metastatic (de-novo or recurrent) non-squamous non-small cell lung cancer (NSCLC) using comprehensive genomic profiling (CGP).



The ASPiRATION program was the first of its kind in Australia to generate high-quality, real-world data about the impact and value of comprehensive genomic profiling (CGP) in delivering precision medicine and personalised healthcare. Identifying actionable molecular targets through CGP provides patients with opportunities to receive novel targeted treatments via therapeutic substudies.


ASPiRATION recruitment is now complete. Any patients who would have been eligible for ASPiRATION will be able to access CGP and the ASPiRATION substudies via Omico’s new program CaSP (Cancer Screening Program). You can read more about this milestone and process here.